AstraZeneca's stock slid more than 6% in early trading on Monday following reports that the British pharmaceutical heavyweight had engaged in preliminary discussions with U.S.-based Bristol Myers Squibb about a potential merger. Such a combination would create one of the world's largest drugmakers, with a combined market value approaching $400 billion.
According to a person familiar with the matter, the companies have explored a possible union, confirming an earlier report by the Financial Times. While a deal could materialize soon, the talks might also be delayed or collapse entirely, the reports indicated.
The market's reaction was swift and negative, with shares also falling over 6% in U.S. premarket trading. Investors struggled to see the strategic rationale, given AstraZeneca's robust standalone growth prospects.
Investors question the strategic fit
"A combination with Bristol does not make strategic or financial sense," said Markus Manns, portfolio manager at Union Investment, an AstraZeneca shareholder. "Many past mega-mergers have destroyed value and there is no apparent need for Astra to do it."
Jefferies analysts, led by Michael Leuchten, echoed those doubts. "Why is perhaps not yet clear to us: we suspect that most people will focus on the potential to establish an even bigger oncology powerhouse, with the resultant portfolio likely the broadest in the industry. However, beyond the regulatory hurdles we would argue that pipeline assets could be sourced elsewhere, as AstraZeneca has been doing, particularly in China."
Chris Beauchamp, chief market analyst at IG, highlighted the political implications of a larger U.S. footprint. "Though a rare example of a big UK firm buying a smaller US firm is something to warm the cockles of the British heart, it risks the departure of yet another national champion, and in any case the pair's large cancer divisions is a major hurdle to a successful deal. BMS has struggled since 2023, and some Astra shareholders will wonder at the need to do expensive M&A when their shares are doing so well."
A deal would reshape the pharmaceutical landscape
Based on Friday's closing valuations, AstraZeneca was worth approximately $264.1 billion, while Bristol Myers Squibb carried a market capitalization of roughly $133.4 billion. A merger would create a pharmaceutical group valued at nearly $400 billion, making it the world's fourth-largest listed drugmaker by market capitalization and one of the largest healthcare deals ever completed.
Such a transaction would significantly expand AstraZeneca's presence in the United States, a market that already accounts for nearly half of the company's revenue. The company has committed to investing $50 billion in U.S. research and manufacturing by 2030 and completed a direct listing on the New York Stock Exchange in June. A takeover of Bristol Myers would further strengthen its American footprint while reviving concerns in Britain about major listed companies shifting their focus away from the UK. The direct listing itself had already been viewed as a setback for London's equity market.
Growth ambitions already on track
AstraZeneca has set an ambitious target of generating $80 billion in annual revenue by 2030, up from $58.7 billion last year. Despite those expansion plans, Chief Executive Sir Pascal Soriot recently suggested that acquisitions were not essential to achieving the company's objectives. Speaking to reporters last week, Soriot said AstraZeneca did not "need M&A to deliver" its 2030 revenue target. Instead, the company has focused on licensing agreements and partnerships, particularly in China, to strengthen its pipeline of experimental medicines.
Any acquisition of Bristol Myers would dwarf AstraZeneca's previous largest transaction—the $39 billion purchase of rare disease specialist Alexion in 2021. For Bristol Myers, a deal could offer an opportunity to address years of underperformance. The U.S. drugmaker has struggled since its $74 billion acquisition of Celgene in 2019 failed to deliver the expected returns. At the same time, the company faces significant revenue pressure as several of its blockbuster medicines approach patent expiry.
That backdrop has led some investors to view Bristol Myers as a potential takeover target, although combining two companies with extensive oncology portfolios would likely invite close scrutiny from regulators. With both companies among the world's leading cancer drug developers, analysts expect any merger proposal to face significant antitrust hurdles before receiving approval.
This article is for informational purposes only and does not constitute financial advice.
